Archive: Chancellor Provides Update on Administrative, Operational Project
UCSF Chancellor Sue Desmond-Hellmann today updated the University community on the progress of the administrative and operating efficiencies work group.
University of California San Francisco
UCSF Chancellor Sue Desmond-Hellmann today updated the University community on the progress of the administrative and operating efficiencies work group.
A panel of experts appointed by Mayor Gavin Newsom recently presented an action plan as the approaching “age wave may bring a potential crisis in Alzheimer’s and dementia care” to San Francisco.
John Greenspan, whose dental and oral health research has led to major contributions to HIV research and care, is the recipient of the 2010 American Association for Dental Research Distinguished Scientist Award.
UCSF researchers have identified a molecular mechanism that explains why patients with tumors of the thymus, or thymoma, often develop autoimmune disorders.
Two doctors are now accepting patients at a new primary care group practice at UCSF’s Mount Zion campus.
Senator Arlen Specter visited UCSF last week talking about health care reform -- the topic of today’s nationally televised summit in Washington DC.
Gary Schlimgen, director of pension and retirement programs at the University of California Office of the President, answers questions about the restart of contributions to the UC Retirement Plan. <a href="http://www.universityofcalifornia.edu/news/article/22856">Read more on the UC website</a>.
A new discovery about cancer and the immune system points to previously unrecognized targets for drug development to battle solid tumors.
UCSF Chancellor Sue Desmond-Hellmann, MD, MPH, today named Jeffrey Bluestone as executive vice chancellor and provost, pending approval by the UC Regents.
Mission Bay Capital, LLC, has added a new limited partner to its first venture fund, bolstering the fund’s ability to invest in promising bioscience companies emerging from the University of California.
Cancer researchers studying the immune system have identified a previously unrecognized set of targets and biomarkers to battle solid tumors.
Kimbery Topp, chair of the Department of Physical Therapy and Rehabilitation Science, has been named a fellow of the American Association of Anatomists.
Walter S. Newman, a leading San Francisco businessman, philanthropist, and community leader, has joined the Board of Directors of NCIRE-The Veterans Health Research Institute.
UCSF has launched a family-friendly web portal and is conducting a survey on family needs with the goal of increasing the availability and access of family programs, services and events.
Nominations for the Chancellor’s Award for Gay, Lesbian, Bisexual and/or Transgender (GLBT) Leadership are due by 5 p.m. on March 31.
UCSF Chancellor Sue Desmond-Hellmann told House Speaker Nancy Pelosi federal economic stimulus funds will help University scientists conduct “biomedical research that literally will change the world.”
People with symptoms of depression in middle age have a significantly greater risk in old age of being physically disabled or unable to carry out tasks of daily living, according to a study led by researchers at the San Francisco VA Medical Center and the University of California, San Francisco.
A UCSF group recommends that egg and sperm donors for in-vitro fertilization be provided information on possible use of embryos in stem cell research.
UCSF nephrologist Flavio Vincenti, MD, is the lead author of a paper in the March 2010 issue of the <i>American Journal of Transplantation</i> that reports results from a Phase III clinical trial for a new drug that selectively blocks immune suppression for kidney transplants. The drug, belatacept, is given to kidney-transplant recipients to prevent the immune system from rejecting the new organ. Vincenti and his co-investigators found that belatacept may be as effective as the commonly used anti-rejection drug cyclosporine, but with fewer side effects and superior kidney function after 12 months.
Two UCSF scientists have been selected for the prestigious Potamkin Prize for their “outstanding achievements” in dementia research.